245 related articles for article (PubMed ID: 36604531)
21. Carrier-Free Nanomedicine for Cancer Immunotherapy.
Fu Y; Bian X; Li P; Huang Y; Li C
J Biomed Nanotechnol; 2022 Apr; 18(4):939-956. PubMed ID: 35854464
[TBL] [Abstract][Full Text] [Related]
22. Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions.
Liu J; Zhang R; Xu ZP
Small; 2019 Aug; 15(32):e1900262. PubMed ID: 30908864
[TBL] [Abstract][Full Text] [Related]
23. Temperature sensitive liposome based cancer nanomedicine enables tumour lymph node immune microenvironment remodelling.
Fu S; Chang L; Liu S; Gao T; Sang X; Zhang Z; Mu W; Liu X; Liang S; Yang H; Yang H; Ma Q; Liu Y; Zhang N
Nat Commun; 2023 Apr; 14(1):2248. PubMed ID: 37076492
[TBL] [Abstract][Full Text] [Related]
24. Low-dose irradiation for reversing immunotherapy resistance: how to translate?
Ochoa-de-Olza M; Bourhis J; Coukos G; Herrera FG
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35835490
[TBL] [Abstract][Full Text] [Related]
25. Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy.
Li W; Peng A; Wu H; Quan Y; Li Y; Lu L; Cui M
Front Immunol; 2020; 11():601497. PubMed ID: 33408716
[TBL] [Abstract][Full Text] [Related]
26. Cancer nanomedicine meets immunotherapy: opportunities and challenges.
Sun Q; Bai X; Sofias AM; van der Meel R; Ruiz-Hernandez E; Storm G; Hennink WE; De Geest B; Kiessling F; Yu HJ; Lammers T; Shi Y
Acta Pharmacol Sin; 2020 Jul; 41(7):954-958. PubMed ID: 32555445
[TBL] [Abstract][Full Text] [Related]
27. Nanomedicines for cancer therapy: current status, challenges and future prospects.
Bor G; Mat Azmi ID; Yaghmur A
Ther Deliv; 2019 Feb; 10(2):113-132. PubMed ID: 30678550
[TBL] [Abstract][Full Text] [Related]
28. Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages.
Li X; Guo X; Ling J; Tang Z; Huang G; He L; Chen T
Nanoscale; 2021 Mar; 13(9):4705-4727. PubMed ID: 33625411
[TBL] [Abstract][Full Text] [Related]
29. Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy.
Wei X; Wang J; Liang M; Song M
Theranostics; 2022; 12(18):7821-7852. PubMed ID: 36451865
[TBL] [Abstract][Full Text] [Related]
30. Considerations for designing preclinical cancer immune nanomedicine studies.
Jiang W; Wang Y; Wargo JA; Lang FF; Kim BYS
Nat Nanotechnol; 2021 Jan; 16(1):6-15. PubMed ID: 33349682
[TBL] [Abstract][Full Text] [Related]
31. Cancer Nanomedicines in an Evolving Oncology Landscape.
Guo P; Huang J; Moses MA
Trends Pharmacol Sci; 2020 Oct; 41(10):730-742. PubMed ID: 32873407
[TBL] [Abstract][Full Text] [Related]
32. Prodrug-Based Versatile Nanomedicine for Enhancing Cancer Immunotherapy by Increasing Immunogenic Cell Death.
Bai S; Yang LL; Wang Y; Zhang T; Fu L; Yang S; Wan S; Wang S; Jia D; Li B; Xue P; Kang Y; Sun ZJ; Xu Z
Small; 2020 May; 16(19):e2000214. PubMed ID: 32309900
[TBL] [Abstract][Full Text] [Related]
33. Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.
Huinen ZR; Huijbers EJM; van Beijnum JR; Nowak-Sliwinska P; Griffioen AW
Nat Rev Clin Oncol; 2021 Aug; 18(8):527-540. PubMed ID: 33833434
[TBL] [Abstract][Full Text] [Related]
34. Dynamic immuno-nanomedicines in oncology.
Ling H; Zhang Q; Luo Q; Ouyang D; He Z; Sun J; Sun M
J Control Release; 2024 Jan; 365():668-687. PubMed ID: 38042376
[TBL] [Abstract][Full Text] [Related]
35. Nanomedicine-mediated regulated cell death in cancer immunotherapy.
Sun Y; Lian T; Huang Q; Chang Y; Li Y; Guo X; Kong W; Yang Y; Zhang K; Wang P; Wang X
J Control Release; 2023 Dec; 364():174-194. PubMed ID: 37871752
[TBL] [Abstract][Full Text] [Related]
36. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
Yang J; Zhang C
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
[TBL] [Abstract][Full Text] [Related]
37. Nanocatalysts for modulating antitumor immunity: fabrication, mechanisms and applications.
Wu X; Li Y; Wen M; Xie Y; Zeng K; Liu YN; Chen W; Zhao Y
Chem Soc Rev; 2024 Mar; 53(5):2643-2692. PubMed ID: 38314836
[TBL] [Abstract][Full Text] [Related]
38. Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects.
Zhang P; Xiao Y; Sun X; Lin X; Koo S; Yaremenko AV; Qin D; Kong N; Farokhzad OC; Tao W
Med; 2023 Mar; 4(3):147-167. PubMed ID: 36549297
[TBL] [Abstract][Full Text] [Related]
39. Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines.
Lynn GM; Laga R; Jewell CM
Cancer Lett; 2019 Sep; 459():192-203. PubMed ID: 31185250
[TBL] [Abstract][Full Text] [Related]
40. Nanomedicine-based tumor photothermal therapy synergized immunotherapy.
Shang T; Yu X; Han S; Yang B
Biomater Sci; 2020 Oct; 8(19):5241-5259. PubMed ID: 32996922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
